Cancer therapy – molecular targets in tumour–host interactions

por Kurschat, P, Mauch, C
Publicado 2006

Membrane-type 1 matrix metalloproteinase-mediated progelatinase A activation in non-tumorigenic and tumorigenic humaneratinocytes

por Baumann, P, Zigrino, P, Mauch, C, Breitkreutz, D, Nischt, R
Publicado 2000

Successful Treatment of a Panniculitis-Like Primary Cutaneous T-Cell Lymphoma of the α/β Type with Bexarotene

por Zhang, X., Schlaak, M., Fabri, M., Mauch, C., Kurschat, P.
Publicado 2012

MGMT gene promoter methylation correlates with tolerance of temozolomide treatment in melanoma but not with clinical outcome

por Hassel, J C, Sucker, A, Edler, L, Kurzen, H, Moll, I, Stresemann, C, Spieth, K, Mauch, C, Rass, K, Dummer, R, Schadendorf, D
Publicado 2010

Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

por Urbonas, V, Schadendorf, D, Zimmer, L, Danson, S, Marshall, E, Corrie, P, Wheater, M, Plummer, E, Mauch, C, Scudder, C, Goff, M, Love, S B, Mohammed, S B, Middleton, M R
Publicado 2019